As the Australian market continues to navigate the economic landscape shaped by the new Trump administration, the ASX200 has shown resilience, closing up 0.36% at 8,408 points amid positive tariff developments. In this environment of cautious optimism, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business and may offer potential stability in a fluctuating market.
Name | Insider Ownership | Earnings Growth |
Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 26.2% |
SKS Technologies Group (ASX:SKS) | 29.7% | 24.8% |
Medallion Metals (ASX:MM8) | 13.8% | 67.5% |
Acrux (ASX:ACR) | 20.2% | 91.8% |
Brightstar Resources (ASX:BTR) | 16.2% | 84.1% |
Newfield Resources (ASX:NWF) | 31.5% | 72.1% |
AVA Risk Group (ASX:AVA) | 15.8% | 77.3% |
Pointerra (ASX:3DP) | 23.8% | 126.4% |
Plenti Group (ASX:PLT) | 12.7% | 120.1% |
Findi (ASX:FND) | 35.8% | 110.7% |
Click here to see the full list of 89 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Simply Wall St Growth Rating: ★★★★★★
Overview: Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and other international markets with a market cap of A$591.37 million.
Operations: The company's revenue is primarily generated from its Biopharmaceutical Sector, amounting to A$88.18 million.
Insider Ownership: 10.4%
Clinuvel Pharmaceuticals demonstrates strong growth potential with earnings projected to grow 26.17% annually, outpacing the Australian market's 12.6%. Revenue is similarly forecasted to increase by 21.4% per year, surpassing the market's 6.1%. The company trades at a significant discount compared to its estimated fair value and peers, with no substantial insider trading activity reported recently. Recent events include addressing shareholder queries on vitiligo treatments and participating in a healthcare conference.
Simply Wall St Growth Rating: ★★★★★★
Overview: Develop Global Limited, along with its subsidiaries, focuses on the exploration and development of mineral resource properties in Australia and has a market cap of A$660 million.
Operations: The company generates revenue primarily from its mining services segment, which amounted to A$147.23 million.
Insider Ownership: 20.4%
Develop Global is positioned for substantial growth, with revenue projected to increase by 56.2% annually, significantly outpacing the Australian market's average. The company is expected to achieve profitability within three years, marking an above-average profit growth rate. Despite no recent insider trading activity, Develop Global trades at a favorable value compared to industry peers. Recent presentations at key conferences highlight ongoing engagement and strategic direction under Managing Director Bill Beament's leadership.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Guzman y Gomez Limited owns, operates, and franchises quick service restaurants in Australia, Singapore, Japan, and the United States with a market cap of A$4.04 billion.
Operations: The company generates revenue primarily from its quick service restaurant operations, amounting to A$364.99 million.
Insider Ownership: 12.8%
Guzman y Gomez is experiencing rapid growth, with revenue increasing by 31.9% last year and forecasted to grow 18% annually, outpacing the Australian market. Insiders have shown confidence through recent substantial share purchases. Despite expected profitability within three years, its projected return on equity remains low at 11.7%. Recent inclusion in the S&P Global BMI Index and board changes mark significant developments for the company as it navigates its growth trajectory.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include ASX:CUV ASX:DVP and ASX:GYG.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.